Loyal is a clinical-stage veterinary medicine company dedicated to extending the healthspan and lifespan of dogs. They develop drugs that target the underlying mechanisms of aging to prevent or delay the onset of age-related diseases. Loyal currently has three drugs in development, with LOY-002 for senior dogs anticipated to be available in early 2025, pending FDA conditional approval. Their mission is to help dogs live longer, healthier lives, providing more quality years with their families.